CA2360019A1 - Anticorps anti-ccr1 et procedes d'utilisation correspondants - Google Patents

Anticorps anti-ccr1 et procedes d'utilisation correspondants Download PDF

Info

Publication number
CA2360019A1
CA2360019A1 CA002360019A CA2360019A CA2360019A1 CA 2360019 A1 CA2360019 A1 CA 2360019A1 CA 002360019 A CA002360019 A CA 002360019A CA 2360019 A CA2360019 A CA 2360019A CA 2360019 A1 CA2360019 A1 CA 2360019A1
Authority
CA
Canada
Prior art keywords
antibody
ccr1
receptor
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002360019A
Other languages
English (en)
Inventor
Shixin Qin
Walter Newman
Nasim Kassam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/001915 external-priority patent/WO2000044789A1/fr
Priority claimed from US09/239,938 external-priority patent/US6329510B1/en
Application filed by Individual filed Critical Individual
Publication of CA2360019A1 publication Critical patent/CA2360019A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à un anticorps ou à un fragment fonctionnel de celui-ci, qui se fixent à un récepteur de CC-chémokine de type 1 (CCR1) de mammifères (par exemple l'homme) ou à une partie de ce récepteur et qui bloquent la fixation d'un ligand à ce récepteur. Cette invention se rapporte en outre à un procédé permettant d'inhiber l'interaction d'une cellule portant un récepteur CCR1 de mammifères avec un ligand de celui-ci, et à l'utilisation de ces anticorps et de ces fragments dans les domaines de la recherche, de la thérapie, de la prophylaxie et du diagnostic.
CA002360019A 1999-01-29 1999-03-02 Anticorps anti-ccr1 et procedes d'utilisation correspondants Abandoned CA2360019A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US1999/001915 WO2000044789A1 (fr) 1999-01-29 1999-01-29 Anticorps anti-ccr1 et methode d'utilisation desdits anticorps
US09/239,938 1999-01-29
USPCT/US99/01915 1999-01-29
US09/239,938 US6329510B1 (en) 1999-01-29 1999-01-29 Anti-CCR1 antibodies and methods of use therefor
PCT/US1999/004527 WO2000044790A1 (fr) 1999-01-29 1999-03-02 Anticorps anti-ccr1 et procedes d'utilisation correspondants

Publications (1)

Publication Number Publication Date
CA2360019A1 true CA2360019A1 (fr) 2000-08-03

Family

ID=26795389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002360019A Abandoned CA2360019A1 (fr) 1999-01-29 1999-03-02 Anticorps anti-ccr1 et procedes d'utilisation correspondants

Country Status (5)

Country Link
EP (1) EP1151011A1 (fr)
JP (1) JP2003517810A (fr)
AU (1) AU772316B2 (fr)
CA (1) CA2360019A1 (fr)
WO (1) WO2000044790A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06005941A (es) * 2003-12-10 2006-08-23 Medarex Inc Anticuerpos ip-10 y sus usos.
EP3067415A1 (fr) * 2004-02-26 2016-09-14 Immunovative Therapies, Ltd. Procédés de préparation de lymphocytes t pour thérapie cellulaire
WO2005091956A2 (fr) * 2004-03-05 2005-10-06 Chiron Corporation Systeme de tests in vitro permettant de predire la tolerabilite d'agents therapeutiques chez des patients
WO2014064192A1 (fr) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé et composition pharmaceutique pour l'utilisation dans le traitement et la prédiction d'un infarctus du myocarde
JP2019048770A (ja) * 2016-01-20 2019-03-28 協和発酵キリン株式会社 抗ヒトｃｃｒ１モノクローナル抗体
WO2019017401A1 (fr) * 2017-07-18 2019-01-24 協和発酵キリン株式会社 Anticorps monoclonal anti-ccr1 humain

Also Published As

Publication number Publication date
AU772316B2 (en) 2004-04-22
EP1151011A1 (fr) 2001-11-07
AU2887399A (en) 2000-08-18
WO2000044790A1 (fr) 2000-08-03
JP2003517810A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
US6756035B2 (en) Anti-CCR1 antibodies and methods of use therefor
CA2336250C (fr) Anticorps anti-ccr2 et procedes d'utilisation correspondants
US6488930B1 (en) Anti-CCR4 antibodies and methods of use therefor
AU772316B2 (en) Anti-CCR1 antibodies and methods of use therefor
WO2000044789A1 (fr) Anticorps anti-ccr1 et methode d'utilisation desdits anticorps
AU2004200923A1 (en) Anti-CCR1 antibodies and methods of use thereof
MXPA01007562A (en) Anti-ccr1 antibodies and methods of use therefor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead